The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.

By I. Roberts, H. Shakur, A. Afolabi, K. Brohi, T. Coats, Y. Dewan, S. Gando, G. Guyatt, B. Hunt, C. Morales and 3 more. The Lancet, 2011

1,109 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

TEG and ROTEM: Technology and clinical applications (2014, neutral): “While the CRASH-2 trial concludes that early treatment with the antifibrinolytic agent tranexamic acid improves survival in trauma patients it is important to note that patients in this trial did not undergo diagnostic testing to detect fibrinolysis [27].”
The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition (2019, methodology): “An unplanned subgroup analysis of the CRASH-2 data [501] showed that early treatment (≤ 1 h from injury) significantly reduced the risk of death due to bleeding by 2.”
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, methodology): “7 8 An unplanned subgroup analysis of the CRASH-2 data [415] showed that early treatment 9 (≤1 h from injury) significantly reduced the risk of death due to bleeding by 2.”
Management of bleeding and coagulopathy following major trauma: an updated European guideline (2013, methodology): “A further analysis of the CRASH-2 data [323] showed that early treatment (≤1 h from injury) significantly reduced the risk of death due to bleeding (198/3,747 (5.”